| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/JVI.77.2.1653-1657.2003 |
| P8608 | Fatcat ID | release_cxzm7ffncbhmvgzzyr4rzyp3la |
| P3181 | OpenCitations bibliographic resource ID | 4470355 |
| P932 | PMC publication ID | 140839 |
| P698 | PubMed publication ID | 12502885 |
| P50 | author | Kathryn A. Hanley | Q24809595 |
| Stephen S Whitehead | Q64866574 | ||
| Brian R. Murphy | Q65658906 | ||
| P2093 | author name string | Barry Falgout | |
| Lewis Markoff | |||
| Joseph E Blaney Jr | |||
| P2860 | cites work | Identification of specific nucleotide sequences within the conserved 3'-SL in the dengue type 2 virus genome required for replication | Q24523550 |
| Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noncoding region and nonstructural proteins 1 and 3 | Q27469644 | ||
| Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine | Q27469646 | ||
| Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine | Q27469921 | ||
| Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys | Q27472847 | ||
| Secondary structure of the 3'-noncoding region of flavivirus genomes: comparative analysis of base pairing probabilities | Q27472948 | ||
| Secondary structure of the 3' untranslated region of flaviviruses: similarities and differences | Q27473202 | ||
| Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys | Q27480386 | ||
| Infectious RNA transcripts from full-length dengue virus type 2 cDNA clones made in yeast | Q27480837 | ||
| Widespread intra-serotype recombination in natural populations of dengue virus | Q27485173 | ||
| Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences | Q29620940 | ||
| Development of a novel mouse model for dengue virus infection | Q33330448 | ||
| Impact of dengue/dengue hemorrhagic fever on the developing world | Q33784757 | ||
| Natural genetic exchanges between vaccine and wild poliovirus strains in humans. | Q39612254 | ||
| Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells | Q40575878 | ||
| A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. | Q40593111 | ||
| Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. | Q40593118 | ||
| Construction of a full length infectious clone for dengue-1 virus Western Pacific,74 strain | Q40623323 | ||
| Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells | Q40646524 | ||
| The 3'-nucleotides of flavivirus genomic RNA form a conserved secondary structure | Q40806302 | ||
| Comparative susceptibility of five species of Toxorhynchites mosquitoes to parenteral infection with dengue and other flaviviruses | Q40817124 | ||
| Comparative susceptibility of mosquito species and strains to oral and parenteral infection with dengue and Japanese encephalitis viruses. | Q40818653 | ||
| P433 | issue | 2 | |
| P921 | main subject | vaccine | Q134808 |
| Dengue virus | Q476209 | ||
| attenuated vaccine | Q1810913 | ||
| P304 | page(s) | 1653-7 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | A Live, Attenuated Dengue Virus Type 1 Vaccine Candidate with a 30-Nucleotide Deletion in the 3' Untranslated Region Is Highly Attenuated and Immunogenic in Monkeys | |
| P478 | volume | 77 |
| Q89552802 | A Review on Dengue Vaccine Development |
| Q40255696 | A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates |
| Q37812291 | A molecular evaluation of dengue virus pathogenesis and its latest vaccine strategies |
| Q33919503 | A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis |
| Q33988937 | A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial |
| Q27472824 | A tick-borne Langat virus mutant that is temperature sensitive and host range restricted in neuroblastoma cells and lacks neuroinvasiveness for immunodeficient mice |
| Q97521587 | Anti-dengue Vaccines: From Development to Clinical Trials |
| Q40148807 | Attenuated dengue 2 viruses with deletions in capsid protein derived from an infectious full-length cDNA clone |
| Q33839001 | Bioinformatics in new generation flavivirus vaccines |
| Q38140035 | Challenges in reducing dengue burden; diagnostics, control measures and vaccines |
| Q40100844 | Characterization of retrovirus-based reporter viruses pseudotyped with the precursor membrane and envelope glycoproteins of four serotypes of dengue viruses |
| Q40474846 | Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. |
| Q38605190 | Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine. |
| Q27486117 | Comparative Neuropathogenesis and Neurovirulence of Attenuated Flaviviruses in Nonhuman Primates |
| Q40500583 | Comparison of live and inactivated tick-borne encephalitis virus vaccines for safety, immunogenicity and efficacy in rhesus monkeys |
| Q40192375 | Complete genome sequencing and evolutionary phylogeography analysis of Indian isolates of Dengue virus type 1. |
| Q35854520 | Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody |
| Q42980788 | Core protein-mediated 5'-3' annealing of the West Nile virus genomic RNA in vitro |
| Q33408300 | Current progress in dengue vaccines |
| Q91711499 | Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade |
| Q26700082 | Dengue Fever: Causes, Complications, and Vaccine Strategies |
| Q38614539 | Dengue epidemiology and pathogenesis: images of the future viewed through a mirror of the past. |
| Q35625026 | Dengue epidemiology: virus epidemiology, ecology, and emergence |
| Q42996339 | Dengue infection. |
| Q33800244 | Dengue type four viruses with E-Glu345Lys adaptive mutation from MRC-5 cells induce low viremia but elicit potent neutralizing antibodies in rhesus monkeys |
| Q37194772 | Dengue vaccines for travelers |
| Q34109652 | Dengue vaccines: state of the art. |
| Q27485404 | Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4 |
| Q42989483 | Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003, Vienna, Austria |
| Q28298464 | Dengue: a continuing global threat |
| Q59352698 | Dengue: a growing threat requiring vaccine development for disease prevention |
| Q64099613 | Detection of post-vaccination enhanced dengue virus infection in macaques: An improved model for early assessment of dengue vaccines |
| Q35206695 | Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine |
| Q36131929 | Economic Burden of Dengue Virus Infection at the Household Level Among Residents of Puerto Maldonado, Peru. |
| Q27860800 | Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses |
| Q56794148 | Epitope Sequences in Dengue Virus NS1 Protein Identified by Monoclonal Antibodies |
| Q34522384 | Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. |
| Q36846290 | Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics |
| Q43222593 | Identification of European bat lyssavirus isolates with short genomic insertions |
| Q92001054 | Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine |
| Q57084668 | Insights into dengue virus genome replication |
| Q40528042 | Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity |
| Q30395396 | Issues related to recent dengue vaccine development |
| Q40549292 | Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus |
| Q37213365 | Mouse models of dengue virus infection and disease |
| Q27477548 | Murine Model for Dengue Virus-Induced Lethal Disease with Increased Vascular Permeability |
| Q29619608 | Prospects for a dengue virus vaccine |
| Q35941645 | Prospects for the therapy and prevention of dengue virus infections |
| Q60917374 | RNA Structure Duplication in the Dengue Virus 3' UTR: Redundancy or Host Specificity? |
| Q91711978 | Rapid Induction and Maintenance of Virus-Specific CD8+ TEMRA and CD4+ TEM Cells Following Protective Vaccination Against Dengue Virus Challenge in Humans |
| Q40256995 | Rational discovery of dengue type 2 non-competitive inhibitors. |
| Q35728621 | Recent advancement in flavivirus vaccine development |
| Q38303232 | Recent progress in dengue vaccine development |
| Q27469474 | Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys |
| Q27487570 | Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2 |
| Q42984608 | Reprint of: Core protein-mediated 5'-3' annealing of the West Nile virus genomic RNA in vitro |
| Q36102687 | Review on flavivirus vaccine development. Proceedings of a meeting jointly organised by the World Health Organization and the Thai Ministry of Public Health, 26-27 April 2004, Bangkok, Thailand |
| Q40400756 | Role of RNA structures present at the 3'UTR of dengue virus on translation, RNA synthesis, and viral replication |
| Q29365117 | Screening for immune response against Dengue virus in Vietnamese non-human primates: implications for vaccine developers |
| Q26252507 | Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection |
| Q27487528 | Structural and Functional Studies of the Promoter Element for Dengue Virus RNA Replication |
| Q91504560 | Structure and function of cis-acting RNA elements of flavivirus |
| Q36118259 | Targeted mutagenesis as a rational approach to dengue virus vaccine development |
| Q36192685 | Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation |
| Q32183359 | The 5' and 3' Untranslated Regions of the Flaviviral Genome |
| Q33817714 | The Role of Heterotypic DENV-specific CD8+T Lymphocytes in an Immunocompetent Mouse Model of Secondary Dengue Virus Infection |
| Q37324444 | The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers |
| Q34036778 | The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome |
| Q37135489 | The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. |
| Q35069160 | The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein |
| Q37350360 | Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses |
| Q34238916 | Utility, limitations, and future of non-human primates for dengue research and vaccine development |
| Q24805308 | Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2 |
| Q27478162 | Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1 |
| Q35172628 | Vaccines for the prevention of neglected diseases--dengue fever |
Search more.